A detailed history of Bank Of America Corp transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 1,703 shares of KZR stock, worth $12,755. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,703
Previous 105,389 98.38%
Holding current value
$12,755
Previous $63,000 98.41%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.53 - $0.77 $54,953 - $79,838
-103,686 Reduced 98.38%
1,703 $1,000
Q2 2024

Aug 14, 2024

BUY
$0.6 - $0.92 $43,284 - $66,368
72,140 Added 216.97%
105,389 $63,000
Q1 2024

May 15, 2024

SELL
$0.8 - $1.05 $44,793 - $58,791
-55,992 Reduced 62.74%
33,249 $29,000
Q4 2023

Feb 14, 2024

BUY
$0.72 - $1.15 $27,676 - $44,204
38,439 Added 75.66%
89,241 $84,000
Q2 2023

Aug 14, 2023

SELL
$2.31 - $3.06 $616,649 - $816,860
-266,948 Reduced 84.01%
50,802 $124,000
Q1 2023

May 12, 2023

SELL
$3.13 - $7.31 $86,312 - $201,580
-27,576 Reduced 7.99%
317,750 $994,000
Q4 2022

Feb 10, 2023

BUY
$6.39 - $8.8 $725,245 - $998,773
113,497 Added 48.96%
345,326 $2.43 Million
Q3 2022

Nov 14, 2022

BUY
$7.99 - $10.75 $1.75 Million - $2.36 Million
219,354 Added 1758.35%
231,829 $2 Million
Q2 2022

Aug 12, 2022

SELL
$4.58 - $17.13 $176,229 - $659,128
-38,478 Reduced 75.52%
12,475 $103,000
Q1 2022

May 16, 2022

SELL
$12.3 - $18.33 $1.2 Million - $1.78 Million
-97,207 Reduced 65.61%
50,953 $847,000
Q4 2021

Feb 08, 2022

BUY
$7.44 - $16.72 $684,785 - $1.54 Million
92,041 Added 164.01%
148,160 $2.48 Million
Q3 2021

Nov 15, 2021

BUY
$4.85 - $9.73 $163,217 - $327,443
33,653 Added 149.8%
56,119 $484,000
Q2 2021

Sep 13, 2021

BUY
$4.93 - $6.46 $110,757 - $145,130
22,466 New
22,466 $122,000

Others Institutions Holding KZR

About Kezar Life Sciences, Inc.


  • Ticker KZR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,369,504
  • Market Cap $512M
  • Description
  • Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...
More about KZR
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.